The U.S. Supreme Court made it easier for shareholders to press class action securities-fraud suits, ruling that Amgen must defend against claims that it misled investors about the safety of two drugs for anemia.
Securities-fraud suits backed by Supreme Court in Amgen case
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.